JP2023510724A5 - - Google Patents
Info
- Publication number
- JP2023510724A5 JP2023510724A5 JP2022541649A JP2022541649A JP2023510724A5 JP 2023510724 A5 JP2023510724 A5 JP 2023510724A5 JP 2022541649 A JP2022541649 A JP 2022541649A JP 2022541649 A JP2022541649 A JP 2022541649A JP 2023510724 A5 JP2023510724 A5 JP 2023510724A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- target
- polypeptide
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957780P | 2020-01-06 | 2020-01-06 | |
| US62/957,780 | 2020-01-06 | ||
| PCT/US2021/012364 WO2021142029A1 (en) | 2020-01-06 | 2021-01-06 | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510724A JP2023510724A (ja) | 2023-03-15 |
| JP2023510724A5 true JP2023510724A5 (enExample) | 2024-01-15 |
Family
ID=74418544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541649A Pending JP2023510724A (ja) | 2020-01-06 | 2021-01-06 | アウリスタチン関連化合物、コンジュゲートアウリスタチン化合物、およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20230059690A1 (enExample) |
| EP (2) | EP4087613A1 (enExample) |
| JP (1) | JP2023510724A (enExample) |
| KR (1) | KR20220122659A (enExample) |
| CN (2) | CN114981287A (enExample) |
| AU (1) | AU2021206218A1 (enExample) |
| BR (1) | BR112022013223A2 (enExample) |
| CA (1) | CA3163860A1 (enExample) |
| CL (1) | CL2022001773A1 (enExample) |
| CO (1) | CO2022010796A2 (enExample) |
| EC (1) | ECSP22061054A (enExample) |
| IL (1) | IL294456A (enExample) |
| MX (1) | MX2022008381A (enExample) |
| PE (1) | PE20221574A1 (enExample) |
| PH (1) | PH12022551426A1 (enExample) |
| WO (3) | WO2021142043A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551426A1 (en) * | 2020-01-06 | 2023-11-20 | Cytomx Therapeutics Inc | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| EP4565260A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130080A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| US20260049148A1 (en) | 2022-08-01 | 2026-02-19 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| JP2026513839A (ja) | 2023-04-12 | 2026-05-01 | サイトムエックス セラピューティクス，インク． | マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法 |
| WO2025131025A1 (en) * | 2023-12-21 | 2025-06-26 | Lanova Medicines Development Co., Ltd. | Conjugates of anti-slc34a2 antibody and uses thereof |
| WO2025199352A2 (en) * | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Antibodies specific for solute carrier family 34 member 2 (slc34a2) |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| EP2265283B1 (en) * | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| EP3501546A3 (de) * | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| BR112015030514A2 (pt) * | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| WO2015038426A1 (en) * | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| AU2016218840A1 (en) * | 2015-02-15 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof |
| CA2979219A1 (en) * | 2015-03-10 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind psma |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| BR112018068461A2 (pt) * | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| CA3134344A1 (en) * | 2016-04-06 | 2017-10-12 | Alteogen, Inc. | Antibody-drug conjugate comprising modified antibody |
| US11485792B2 (en) * | 2016-06-06 | 2022-11-01 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| EP3522933B1 (en) * | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| CN108101825B (zh) * | 2016-11-25 | 2022-02-22 | 迈威(上海)生物科技股份有限公司 | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| US11623963B2 (en) * | 2017-10-03 | 2023-04-11 | Merck Patent Gmbh | Cysteine engineered antigen-binding molecules |
| CN110152014B (zh) * | 2018-02-13 | 2022-09-27 | 烟台市和元艾迪斯生物医药科技有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
| WO2019191728A1 (en) * | 2018-03-29 | 2019-10-03 | Ambrx, Inc. | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
| PH12022551426A1 (en) * | 2020-01-06 | 2023-11-20 | Cytomx Therapeutics Inc | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
-
2021
- 2021-01-06 PH PH1/2022/551426A patent/PH12022551426A1/en unknown
- 2021-01-06 EP EP21702787.9A patent/EP4087613A1/en not_active Withdrawn
- 2021-01-06 WO PCT/US2021/012383 patent/WO2021142043A1/en not_active Ceased
- 2021-01-06 EP EP21702784.6A patent/EP4087855A1/en active Pending
- 2021-01-06 US US17/790,842 patent/US20230059690A1/en not_active Abandoned
- 2021-01-06 PE PE2022001386A patent/PE20221574A1/es unknown
- 2021-01-06 IL IL294456A patent/IL294456A/en unknown
- 2021-01-06 WO PCT/US2021/012364 patent/WO2021142029A1/en not_active Ceased
- 2021-01-06 MX MX2022008381A patent/MX2022008381A/es unknown
- 2021-01-06 US US17/790,835 patent/US20230071763A1/en active Pending
- 2021-01-06 WO PCT/US2021/012379 patent/WO2021142039A1/en not_active Ceased
- 2021-01-06 CN CN202180008396.2A patent/CN114981287A/zh active Pending
- 2021-01-06 KR KR1020227023304A patent/KR20220122659A/ko not_active Ceased
- 2021-01-06 US US17/790,838 patent/US20230073692A1/en active Pending
- 2021-01-06 BR BR112022013223A patent/BR112022013223A2/pt not_active IP Right Cessation
- 2021-01-06 CA CA3163860A patent/CA3163860A1/en active Pending
- 2021-01-06 JP JP2022541649A patent/JP2023510724A/ja active Pending
- 2021-01-06 AU AU2021206218A patent/AU2021206218A1/en not_active Abandoned
- 2021-01-06 CN CN202180008260.1A patent/CN114929286A/zh active Pending
-
2022
- 2022-06-29 CL CL2022001773A patent/CL2022001773A1/es unknown
- 2022-08-01 CO CONC2022/0010796A patent/CO2022010796A2/es unknown
- 2022-08-04 EC ECSENADI202261054A patent/ECSP22061054A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3163860A1 (en) | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof | |
| JP2022046569A5 (enExample) | ||
| Kang et al. | Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates | |
| CN111225918B (zh) | 具有三环部分的Toll样受体7(TLR7)激动剂、其缀合物及其方法和用途 | |
| CN112261954B (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| JP6310033B2 (ja) | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 | |
| CN111201228B (zh) | 作为Toll样受体7(TLR7)激动剂的6-氨基-7,9-二氢-8H-嘌呤-8-酮衍生物 | |
| JP2018509394A5 (enExample) | ||
| JP6609563B2 (ja) | ケトンで修飾されたポリペプチドをオキシム複合化する方法 | |
| CA2937600C (en) | Antibody-drug conjugates and immunotoxins | |
| JP2017537893A5 (enExample) | ||
| ES2732574T3 (es) | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro | |
| JP6949832B2 (ja) | タンパク質コンジュゲート | |
| JP2018504925A5 (enExample) | ||
| JP6721572B2 (ja) | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 | |
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| JP2016521707A5 (enExample) | ||
| US20160000933A1 (en) | Conjugated biological molecules and their preparation | |
| JP2024540691A5 (enExample) | ||
| CN102665768A (zh) | 肽清除剂 | |
| CN111278461A (zh) | 可前药化抗体、其前药以及使用和制备方法 | |
| US20240417436A1 (en) | Conditionally activated immunocytokines and methods of use | |
| TW201836647A (zh) | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 | |
| CN1711108A (zh) | 用于免疫球蛋白Fab片段选择性和定量官能化的方法、由其获得的缀合化合物及其组合物 | |
| EP3394096A1 (en) | Variant antibodies for site-specific conjugation |